Call for Abstract
Donard S. Dwyer LSU Health Sciences Center, USA
Jose F Abisambra University of Kentucky, USA
Patrizia LoPresti University of Illinois at Chicago, USA
Hua Su University of California, USA
Sidhartha Tan University of Chicago, USA
Hari Shanker Sharma Uppsala University, Sweden
Kjell Fuxe Karolinska Institutet, Sweden
Carola Forster Wurzburg University, Germany
Cristina Vittoria Dieni University of Perugia, Italy
Mariagrazia Grilli University of Piemonte Orientale, Italy
Marie-Françoise SUAUD-CHAGNY Lyon Neuroscience Research Center, France
Norio Yasui-Furukori Hirosaki University, Japan
4th Global Experts Meeting on Neuropharmacology, will be organized around the theme “Innovations and Complications in Neuropharmacological Studies”
Neuropharmacology 2016 is comprised of 15 tracks and 82 sessions designed to offer comprehensive sessions that address current issues in Neuropharmacology 2016.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
It deals with a branch of immunology concerned with the interactions between immunological and nervous system functions also associated autoimmune diseases such as Encephalitis. Blood brain barrier is a selectively permeable membrane that separates the blood in the brain from other extracellular fluids. Meningitis, epilepsy, cerebral edema, multiple sclerosis etc. are various diseases associated with it.
The children of age group 1 to 14 are more prone to cancer, out of which 18% is the case of brain tumour. In the first three decades of life, central nervous system has emerged as one of the three vulnerable leading sites for cancer mortality. Cerebral lymphoma is the most rapidly increasing brain tumour.
- Track 1-1Cortical systems and their complexicity
- Track 1-2Encephalitis: advanced drug developments
- Track 1-3Transverse myelitis spectrum disorders and prognosis
- Track 1-4Huntington’s disease and linkage with cognitive & psychiatric disorders
- Track 1-5Epigenetics and its role in neuroimmunepharmacology
- Track 1-6Immunopathogenesis of brain tumour
- Track 1-7Blood Brain Barrier and associated disorders
- Track 1-8Epilepsy and epileptic seizures
- Track 1-9Stroke
Molecular neuropharmacology involves the study of neurons and agonist, Competitive antagonist and Non-competitive antagonist, receptors on neurons for developing new drugs that will treat neurological disorders of neurodegenerative diseases. Neurogenesis and repair refers to the growth and development of neuron. Neurons never function in isolation; they are organized into ensembles or circuits that process kinds of information which are referred as neuronal circuits. The GABA inhibitory neurotransmitter and serotonin neurotransmitter present in the central nervous system of mature vertebrate interacts with GABA receptor and 5HT receptor respectively.
The global CNS biomarker market was estimated at $1.7 billion in 2011 and nearly $2 billion in 2012. The market is projected to reach $5.1 billion by the end of the forecast period of 2012 to 2017, representing a compound annual growth rate (CAGR) of 20.7%.
- Track 2-1Neurogenesis and repair
- Track 2-2Studies on neuronal circuits
- Track 2-3GABA , 5HT receptors and its neuronal development
- Track 2-4Synaptopathy in neurodegenerative diseases and ageing
- Track 2-5Manipulation of ion channels by drugs
It is the science that studies the features, properties, interactions, responses and uses of drugs mainly their therapeutic effect in humans along with toxicology, pharmacodynamics and pharmacokinetics. It also includes drug abuse, pain and hypothalamic releasing factors.
The global market for drug discovery technologies reached nearly $39.5 billion and $46.5 billion in 2013 and 2014, respectively. This market is expected to grow at a compound annual growth rate (CAGR) of 11.3% to nearly $79.5 billion for the period 2014-2019.
- Track 3-1Clinical neuropharmacology of drug abuse
- Track 3-2Clinical neuropharmacology and therapeutics
- Track 3-3Clinical neuropharmacology of pain
- Track 3-4Clinical neuropharmacology of hypothalamic releasing factors
Psychopharmacology is the learning of the effects of medication on the psyche (psychology), observing changed behaviors and how molecular events are manifest in a measurable behavioral form. The treatments may cause side effects such as induction of the metabolic syndrome, type II diabetes related to the medications prescribed for management of psychiatric and behavioural disorders and disturbances. The effectiveness of the drugs can be increased by prescriber’s knowledge over emotional and interpersonal issues of the patient i.e. psychology of psychopharmacology. Schizophrenia is such a disorder which affects the thinking and acting ability of a person caused by viral infection, genetically or by immune disorder.
The global mental health pharmaceutical market can be estimated at $80 billion in 2010. This market is expected to increase at a 1.9% compound annual growth rate (CAGR) over the forecast period to reach a value of $88 billion in 2015.
- Track 4-1Psychopharmacology drugs and their interaction with neurotransmitters
- Track 4-2Dose response relation in psychiatric medications
- Track 4-3Effect of androgenic anabolic steroids on psychosis
- Track 4-4Schizophrenia and its dependence on brain chemistry and structure
- Track 4-5Psychology of psychopharmacology
- Track 4-6Preclinical psychopharmacology
- Track 4-7Clinical and translational psychopharmacology
Neurochemistry is the specific study of neurochemicals, including neurotransmitters and other molecules that include psychopharmaceuticals, neuropeptides, or gastrotransmitters that influence the function of neurons. It also deals how these neurochemicals influence the network of neural operation. Presence of an intellectual disability, communication disorder, epilepsy or other genetic disorder is present in approximately 70% of people with ASD.
The global neurostimulation devices market is expected to reach $3.8 billion in 2013 and $4.1 billion in 2018, with a compound annual growth rate (CAGR) of 1.5%.
- Track 5-1Human synapses
- Track 5-2Neuropeptides
- Track 5-3Serotonin
- Track 5-4Dopamine
- Track 5-5Target drugs in summation and cotransmission
- Track 5-6Drug interaction in various stages in neurotransmitters
- Track 5-7Interneurons: coordinators of neuronal synchrony
- Track 5-8Advances in astrocyte-neuron interactions in health and disease.
- Track 5-9Autism and intellectual disability
- Track 5-10Monoamines
It is the study of drug dependence and how drug addiction affects the human mind, Anxiety and Autism, Measuring neural activity in Drug abuse, Alcoholism- tolerance to and physical dependence, and properties are mediated through its effects on dopamine neurons in the mesolimbic reward pathway, which connects the ventral tegmental area to the nucleus accumbens, Post-traumatic stress disorder and borderline personality disorder, clinical depression and enhanced treatments.
The global autism spectrum disorders (ASD) market was valued at $346.2 million in 2013 and $360.9 million in 2014. This market is expected to grow to $412.7 million by 2019, a compound annual growth rate (CAGR) of 2.7%.
- Track 6-1Anxiety and Autism
- Track 6-2Measuring neural activity in drug abuse
- Track 6-3Alcoholism- tolerance to and physical dependence
- Track 6-4Post-traumatic stress disorder and borderline personality disorder
- Track 6-5Clinical depression and enhanced treatments
These are the brain chemicals that connect brain and the body. They transmit signals between nerve cells, called neurons. They can also affect mood, sleep, concentration, weight, and can cause adverse symptoms when they are out of balance. These are of two types: Inhibitory and Excitatory. Acetylcholine, Glutamine and GABA are some of these neurotransmitters.
The global G protein, coupled receptors (GPCR) targeting drug market sharply fell in the last three years due to a series of patent expirations of blockbuster products. The market receded from nearly $111 billion to almost $100 billion with a -3.4% compound annual growth rate (CAGR) between 2010 and 2013. With the introduction of novel pharmacecuticals and newly appearing classes of drugs, Research expects this market to reach $114 billion by 2018, a CAGR of 2.7% from 2013 to 2018.
- Track 7-1Acetylcholine
- Track 7-2Glutamine
- Track 7-3Gamma amino butyric acids (GABA)
It is the measurement and analysis of chemical and electrical signals of nervous system. It includes neurocircuitary analysis, novel trans-synaptic tracing approaches, advancements of optical techniques, neuromodulation and transcranial magnetic stimulation. Neurotechnology plays a crucial role in diagnostics and identification of nervous activities.
The sales of drug-device combination products reached $21.4 billion in 2013 and $22 billion in 2014. This market is expected to grow to $31 billion in 2019, with a compound annual growth rate (CAGR) of 7.1% from 2014 to 2019.
- Track 8-1Modern neurocircuitry analysis
- Track 8-2Novel trans-synaptic tracing approaches
- Track 8-3Transcranial magnetic stimulation
- Track 8-4Optical techniques and advances
- Track 8-5Neuromodulation and implant
It is the study of interactions between the nervous system and the endocrine system, also biological features of the cells involved and their communications. Most Important aspects of neuroendocrinology are insulin receptor and hypothalamic programming; stress, coping and interactions, neuro-endocrine-immune symphony, pituitary structure and hormone secretion.
The global market for Multiple Sclerosis (MS) disease-modifying products reached $10.1 billion in 2012 and nearly $10.9 billion in 2013. This market is expected to grow to nearly $14.2 billion in 2018 with a compound annual growth rate (CAGR) of 5.4% over the five-year period from 2013 to 2018.
- Track 9-1Insulin receptor and hypothalamic programming
- Track 9-2Stress, coping and interactions
- Track 9-3A neuro-endocrine-immune symphony
- Track 9-4Pituitary structure and hormone secretion- New Insights
Alzheimer's is a type of dementia that causes problems with memory, thinking and behaviour. Symptoms usually develop slowly and become severe enough to interfere with daily tasks. Amyloid plaques are also found in the brain of Alzheimer patients. Neurocognitive effects associated with therapeutic drugs and animal cognition and behaviour - Fear and aversive learning and memory.
The global market for alzheimer’s disease reached $10.2 billion in 2012. The market is expected to decrease to $9.5 billion in 2017 for a CAGR of -1.5%.
- Track 10-1Symptoms, causes and diagnostics
- Track 10-2Neurocognitive effects associated with therapeutic drugs
- Track 10-3Animal cognition and behaviour - Fear and aversive learning and memory
- Track 10-4Environmental effects associated with disease
- Track 10-5Role of amyloid protein in Alzheimer
- Track 10-6Drug desigining and therapeutics
It is a progressive and chronic disorder, caused by death or malfunctioning of neurons, genetic mutation leading to decreased level of dopamine secretion. Associated effects are anxiety; depression, stress, ageing and neurodegenerative disorders, disease diagnostics, drug designing and therapeutics are the research areas.
The combined direct and indirect cost of Parkinson’s, including treatment, social security payments and lost income from inability to work, is estimated to be nearly $25 billion per year in the United States alone.Medication costs for an individual person with PD average $2,500 a year, and therapeutic surgery can cost up to $100,000 dollars per patient.
- Track 11-1Impact of genetic mutations
- Track 11-2Interdependent disorders such as neurodegenerative disorders and ageing
- Track 11-3Anxiety, depression and stress level in Parkinson’s
- Track 11-4Approaches involved in diagnostics
- Track 11-5Drug desigining and therapeutics
It includes the social, legal and ethical consequences of advances in neuroscience. It is the amalgamation of neuroscience with ethical thoughts. The ethics of neurocognitive includes brain interventions and imagining, neurological treatments and consciousness disorders.
The global molecular diagnostics market was valued at almost $21.7 billion in 2014. The total market is projected to grow at a compound annual growth rate (CAGR) of 12.5% from 2015 through 2020 to reach nearly $25.2 billion by 2015 and $45.2 billion by 2020.
- Track 12-1Neurological disorders and implications for society
- Track 12-2Brain interventions and Brain imaging
- Track 12-3Neuroethics of neurological treatements and management
- Track 12-4Neuroethics associated with different stages of conciousness and related disorders
Neuropharmacology is an emerging field of science, rising exponentially with the understanding of nervous system and its related disorders, drugs and treatments. The major area of research includes mechanisms of novel drugs, neuro stem cell therapy, immunoglobulin therapy, gene therapy in neuronal disorders and neural engineering.
The global market for medical imaging systems is estimated to be $17 billion in 2009 and is forecast to grow at a compound annual growth rate (CAGR) of 5.8% from 2009 to 2014. Ultrasound systems comprise 29% of the global medical imaging systems market. X-ray systems are next, with a 24% share. Positron emission tomography has seen growth but it is the smallest segment. The X-ray market is growing well due to the introduction of digital technology.
- Track 13-1Novel drugs and their mechanisms
- Track 13-2Neuroprotection
- Track 13-3Neurovirology
- Track 13-4Neurogenetics
- Track 13-5Neurotoxicity
- Track 13-6Neuroscience
- Track 13-7Neuro-Ophthalmology
- Track 13-8Neural engineering
- Track 13-9Gene therapy in neurological disorders
- Track 13-10Neuro stem cell therapy
- Track 13-11Neuro-radiology
Case studies are an extremely useful records of the clinical practices of a profession. They are a record of clinical interactions which help us to frame questions for more rigorously designed clinical studies. Case studies also provide valuable teaching material, demonstrating both classical and unusual presentations which may challenge the practitioner.
The overall emerging markets for therapeutic drugs totaled $131.4 billion in 2009. These regions include Latin America, China, Eastern Europe, the Middle East, South Korea, India, Russia, and South Africa. These regions are estimated at $145.8 billion in 2010 and expected to continue aggressive growth through 2015, reaching a figure of $214.2 billion, yielding a compound annual growth rate (CAGR) of 8% from 2010 to 2015. The global market for blood-brain barrier (BBB) technology for therapeutics amounted to $12.3 million in 2010 and will reach $387 million by 2015, a compound annual growth rate (CAGR) of 99.3%.
- Track 14-1Case Study in USA
- Track 14-2Case Study in World
- Track 14-3Case Study in Women
- Track 14-4Case study in Children
A platform aimed to connect Entrepreneurs, Proposers and the Investors worldwide. It's intended to create and facilitate the most optimized and viable meeting place for engaging people in global business discussions, evaluation and execution of promising business ideas. An investor could be able to find out the highest potential investment opportunities globally, which provide good return on investment. For entrepreneurs, this would be an ideal place to find out suitable investors and partners to start and/or expand their business. Thus it is a perfect place to connect Entrepreneurs, Business Owners, Early Stage Companies and Established Corporates with National or International Investors, Corporate Investors and Potential Business Partners.